| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2008;117:2071-2078.)
© 2008 American Heart Association, Inc.
Interventional Cardiology |
From the University at Albany, State University of New York, Albany (E.L.H.); New York State Department of Health, Albany (M.R.); Mayo Clinic, Rochester, Minn (D.R.H.); St Josephs Hospital, Syracuse, NY (G.W.); Mt Sinai Medical Center, New York, NY (S.S.); North Shore–LIJ Health System, Manhasset, NY (S.K.); Duke University Medical Center, Durham, NC (R.H.J.); and Fuqua Heart Center/Piedmont Hospital, Atlanta, Ga (S.B.K.).
Correspondence to Edward L. Hannan, PhD, School of Public Health, State University of New York, University at Albany, One University Place, Rensselaer, NY 12144–3456. E-mail elh03{at}health.state.ny.us
Received July 10, 2007; accepted January 29, 2008.
Background— Few studies have compared medium-term outcomes for drug-eluting stents (DES) and bare metal stents, and most are relatively small randomized controlled trials. Furthermore, since the introduction of DES, there has been increased use and duration of use of clopidogrel, statins, and other evidence-based therapies. The purpose of the present study was to compare outcomes for patients who underwent stenting in the eras before and after the introduction of DES.
Methods and Results— New York state patients undergoing stenting in all nonfederal hospitals in the state were studied. Patients were excluded if they had a previous revascularization. Risk factors that were significant predictors of adverse outcomes were used to adjust adverse outcome rates. The study included 11 436 patients who received stents between October 1, 2002, and March 31, 2003, and 12 926 patients who underwent stenting between October 1, 2003, and March 31, 2004. Death rates, the combined end point of death and myocardial infarction (MI), nonfatal MI requiring readmission, target vessel revascularization, and target lesion revascularization were compared at 2 years. Patients in the DES era had significantly better risk-adjusted outcomes for death/MI (adjusted hazard ratio, 0.90; 95% confidence interval, 0.83 to 0.97), 9.9% versus 10.8%; nonfatal MI requiring readmission (adjusted hazard ratio, 0.86; 95% confidence interval, 0.76 to 0.97); target vessel revascularization (adjusted hazard ratio, 0.60; 95% confidence interval, 0.56 to 0.64), 11.2% versus 17.9%; and target lesion revascularization (hazard ratio, 0.55; 95% confidence interval, 0.51 to 0.59), 8.4% versus 14.7%.
Conclusions— Patients in the DES era experienced lower rates of death/MI, nonfatal MI, target vessel revascularization, and target lesion revascularization, but there were no differences in the rates of death. These improvements are likely a result of increased use of clopidogrel, statins, and dual antiplatelet therapy, in addition to the introduction of DES.
Related Article:
This article has been cited by other articles:
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF] |
||||
![]() |
G. S. Aldea, N. A. Mokadam, R. Melford Jr, D. Stewart, C. Maynard, M. Reisman, and R. Goss Changing Volumes, Risk Profiles, and Outcomes of Coronary Artery Bypass Grafting and Percutaneous Coronary Interventions. Ann. Thorac. Surg., June 1, 2009; 87(6): 1828 - 1838. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Douglas, J. M. Brennan, K. J. Anstrom, A. Sedrakyan, E. L. Eisenstein, G. Haque, D. Dai, D. F. Kong, B. Hammill, L. Curtis, et al. Clinical Effectiveness of Coronary Stents in Elderly Persons: Results From 262,700 Medicare Patients in the American College of Cardiology-National Cardiovascular Data Registry J. Am. Coll. Cardiol., May 5, 2009; 53(18): 1629 - 1641. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, Z. Zheng, B. Xu, S. Zhang, W. Li, R. Gao, and S. Hu Comparison of Drug-Eluting Stents and Coronary Artery Bypass Surgery for the Treatment of Multivessel Coronary Disease: Three-Year Follow-Up Results From a Single Institution Circulation, April 21, 2009; 119(15): 2040 - 2050. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Cutlip Drug-Eluting or Bare-Metal Stents for ST Elevation Myocardial Infarction Can Observational Data Balance the Risk Benefit Equation? Circ Cardiovasc Interv, December 1, 2008; 1(3): 161 - 163. [Full Text] [PDF] |
||||
![]() |
D.-W. Park, S.-C. Yun, S.-W. Lee, Y.-H. Kim, C. W. Lee, M.-K. Hong, S.-S. Cheong, J.-J. Kim, S.-W. Park, and S.-J. Park Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents J. Am. Coll. Cardiol. Intv., October 1, 2008; 1(5): 494 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents JAMA, June 25, 2008; 299(24): 2868 - 2876. [Abstract] [Full Text] [PDF] |
||||
![]() |
Drug-Eluting Stents: Is the Tide Turning? Journal Watch Cardiology, June 4, 2008; 2008(604): 2 - 2. [Full Text] |
||||
![]() |
B. W. Lytle The Challenge of Left Main Stenosis J. Am. Coll. Cardiol. Intv., June 1, 2008; 1(3): 246 - 247. [Full Text] [PDF] |
||||
![]() |
L. Mauri and S.-L. T. Normand Studies of Drug-Eluting Stents: To Each His Own? Circulation, April 22, 2008; 117(16): 2047 - 2050. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |